JAGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JAGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Jaguar Health's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.
For the Biotechnology subindustry, Jaguar Health's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Jaguar Health's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:
* The bar in red indicates where Jaguar Health's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.
Jaguar Health (NAS:JAGX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation
EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of Jaguar Health's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.
Anula Jayasuriya | director | 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
Pravin R Chaturvedi | officer: Chief Scientific Officer | C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104 |
Lisa A Conte | director, officer: CEO & President | 213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Carol R. Lizak | officer: Chief Accounting Officer | 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
James J Bochnowski | director | C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402 |
Jonathan S. Wolin | officer: Chief of Staff, CCO & GC | 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
Jonathan B. Siegel | director | C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019 |
Bryan Ezralow 1994 Trust Dated December 22, 1994 | 10 percent owner | 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302 |
Bryan Ezralow | 10 percent owner | THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549 |
Nantucket Investments Ltd | 10 percent owner | PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH |
Jonathan M Glaser | 10 percent owner | 11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025 |
Murray David Macnaughtan | director | C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
Greg J Divis | director | 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
Jeffery C. Johnson | director | C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901 |
Sagard Capital Partners, L.p. | 10 percent owner | 280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017 |
From GuruFocus
By ACCESSWIRE • 08-24-2023
By ACCESSWIRE • 11-30-2023
By ACCESSWIRE • 09-12-2023
By ACCESSWIRE • 09-27-2023
By ACCESSWIRE • 10-10-2023
By ACCESSWIRE • 11-02-2023
By ACCESSWIRE • 08-14-2023
By ACCESSWIRE • 08-30-2023
By ACCESSWIRE • 12-04-2023
By ACCESSWIRE • 09-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.